​Switzerland has world-class science, clinical excellence, precision engineering, and a strong biotech innovation culture. China offers complementary capabilities in speed, scale, translational infrastructure, manufacturing, capital access, clinical development, and a rapidly evolving life sciences ecosystem.

​This intimate roundtable explores how Swiss biotech ventures can engage with China in a thoughtful, strategic, and responsible way — not as a shortcut, but as a potential amplifier for R&D, venture building, clinical translation, manufacturing, financing, and market access.

​Drawing on ATLATL’s model of integrated life sciences infrastructure — including lab-space-as-a-service, turnkey R&D solutions, on-site CRO support, cloud labs, and advanced technology platforms — the discussion will examine practical ways Swiss biotech companies can access China’s ecosystem while managing quality, IP, regulatory, governance, and geopolitical risks.

​The session is designed for selected biotech founders, investors, and translational life science leaders. Participants will also have the opportunity to briefly introduce themselves through a short elevator pitch. The goal is to exchange practical insights on how Swiss innovation and China’s ecosystem capabilities can be combined responsibly and effectively to accelerate the path from breakthrough science to patient impact.

​Agenda

​14:30–14:40
Welcome by Jess Jia

​14:40–15:00
Dr. PC Zhu: ATLATL’s biotech infrastructure model — lessons from China, Boston, and cross-border venture building

​15:00–15:45
Moderated roundtable: Swiss biotech × China’s R&D ecosystem — opportunities, risks, and practical collaboration models

​15:45–16:00
Informal networking and light snacks

​Speaker

​Dr. PC Zhu

​Founder and CEO of ATLATL Innovation Center, Dr. PC Zhu is a scientist-entrepreneur building biotech R&D infrastructure and cross-border innovation ecosystems. ATLATL provides integrated life sciences infrastructure in China, including lab-space-as-a-service, turnkey R&D solutions, on-site CRO support, cloud lab capabilities, advanced technology platforms, and venture-building support for entrepreneurs, research institutions, pharma companies, and investors.

​Dr. Zhu completed postdoctoral training at Harvard Medical School, holds an MBA from Chicago Booth, and previously founded Mass Innovation Labs in Boston, helping incubate several biotech IPOs including CRISPR Therapeutics, Editas Medicine, Gritstone Bio, and C4 Therapeutics.

​Moderator

​Jess Jia

​Dr. Jess Jia is a biotech entrepreneur and former cross-border commercial lawyer focused on solid tumor immunotherapy, venture building, and China–Europe biotech translation strategies. She brings experience at the intersection of science, business strategy, legal structuring, and cross-border collaboration.